The immunotherapy nivolumab is a “game-changing” treatment for people with advanced head and neck cancer, British researchers have reported.
The research, published in the latest edition of The Lancet Oncology, found that of the 129 patients on a phase III trial, those on nivolumab consistently reported better quality of life compared with those on chemotherapy.
Patients filled in questionnaires about their quality of life, which covered physical symptoms, mental health and general wellbeing.
After nine weeks, patients treated with nivolumab reported that they were doing better than their counterparts on other treatments for a range of symptoms, including pain, sensory problems, appetite loss, tiredness and breathing problems.
After 15 weeks, the list of beneficial effects was even longer, with patients taking nivolumab being less badly affected by nausea, insomnia and weight loss.
Professor Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research, London, and Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust, said: "Head and neck cancer is an extremely debilitating disease, and if it spreads or patients relapse then it’s extremely difficult to treat.
"But our research has found that nivolumab really is a game-changing treatment for patients with head and neck cancer. Not only does it extend survival, we have now shown that patients feel much better in the extra time that the drug grants them.”
He said there have been significant improvements in managing side effects and doctors are also now better at selecting patients for whom immunotherapies would be effective.
"We now need to test if we can move away from resorting to traditional chemotherapies, which come with far too much collateral damage, and see these smarter, kinder therapies used as a first-line treatment to replace chemotherapy altogether,” he added.
Welcoming the findings, Professor Paul Workman, chief executive of The Institute of Cancer Research, London, said: "Creating cancer treatments that can not only extend life but also minimise the impact of the disease on patients’ lives is a major aim of researchers worldwide.
"So it’s great news that this trial has found that as nivolumab greatly extends life among these patients it also gives marked improvements in quality of life compared with current treatment options.
"I hope that this drug will be now approved very soon for use on the NHS so that this group of patients, who badly need new treatment options, can see the benefit."
Professor David Cunningham, director of Clinical Research at The Royal Marsden NHS Foundation Trust and director of the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research, London, said: "Using the body’s own immune system to attack cancer continues to find wider application across the spectrum of cancers we have to treat in the clinic.
"Head and neck cancer is a particularly challenging disease and these results are an important step in improving outcomes for our patients."
Last year, the clinical trial of 361 patients found that increased survival for people with recurrent or metastatic head and neck cancer.
The drug was initially rejected by NICE in April this year and is now under consultation before a final decision is due.
Harrington K, Ferris R, Blumenschein G et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet 23 June 2017; doi: http://dx.doi.org/10.1016/S1470-2045(17)30421-7 [abstract]

Leave a Reply